9 Analysts Have This to Say About Integra Lifesciences
Portfolio Pulse from Benzinga Insights
Over the last quarter, Integra Lifesciences (NASDAQ:IART) has received mixed analyst ratings. The average price target is $49.89, which is higher than the current price of $44.54. However, this represents an 11.89% decrease from the previous average price target of $56.62.
July 28, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Integra Lifesciences has received mixed analyst ratings over the last quarter, with an average price target of $49.89, which is higher than its current price.
The mixed analyst ratings indicate uncertainty about the company's performance. While the average price target is higher than the current price, suggesting potential upside, it's important to note that this target is down 11.89% from the previous one, indicating a less optimistic outlook.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100